Adopting new prosthetic technology for your patients doesn’t mean taking on risk.
This session explores how clinics are successfully introducing the Metacarpal GEM hand as a low-risk, high-function upper limb solution; under L7499 and evolving reimbursement dynamics.
We’ll break down how to align with payer expectations, build defensible cases, and confidently position Metacarpal GEM as a practical, justifiable option for patients today.
Expect a transparent, real-world discussion grounded in both evidence and early clinical experience.
What You’ll Learn
- How to navigate L7499 without hesitation
- What payers actually look for: function, necessity, and cost justification
- Why “new” doesn’t automatically mean “denied”
- Documentation strategies that strengthen approval outcomes
- How to position GEM as a low-risk pathway to immediate function
- Practical ways to trial and adopt without financial exposure
Agenda
- Opening: Setting the context
- Transparency: Addressing L7499 and normalizing uncertainty
- Understanding the payer mindset (function, medical necessity, cost)
- Building a defensible case: documentation, language, and comparisons
- Evidence vs. experience: using early clinical feedback effectively
- De-risking adoption: demo hands, trial fittings, and expectation setting
- Navigating authorization and reducing financial exposure
- Risk-sharing: when and how it works
- Live Q&A
Who Should Attend
- Prosthetists and clinic owners
- Clinical decision-makers in upper limb prosthetics
- Reimbursement and admin teams
- Innovators exploring new prosthetic solutions
Event Format
Live webinar with interactive Q&A
Key Takeaway
Metacarpal GEM is a low-risk way to deliver immediate function in today’s reimbursement environment.

